Linked Life Data

11427255

Source:http://linkedlifedata.com/resource/pubmed/id/11427255

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
28-29
pubmed:dateCreated
2001-6-27
pubmed:abstractText
Rabies immune globulin (RIG) is essential for post-exposure prophylaxis but is expensive and not widely available. Rabies virus-neutralizing human monoclonal antibodies (Mabs) were evaluated in vitro and in a Syrian hamster model as a potential future alternative. Seven Mabs neutralized representative rabies virus variants. However, a European bat lyssavirus was not neutralized by either Mabs or RIG. Moreover, Duvenhage virus was neutralized by RIG, but not by Mabs, and Lagos bat and Mokola viruses were neutralized by one Mab but not by RIG. In hamsters, one Mab resulted in protection that was comparable to human RIG. These results suggest that Mabs may provide a promising alternative to RIG.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
16
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3834-42
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis.
pubmed:affiliation
Centers for Disease Control and Prevention, Rabies Section MS-G33, 1600 Clifton Road NE, Atlanta, GA 30333, USA. cfh8@cdc.gov
pubmed:publicationType
Journal Article, In Vitro, Research Support, U.S. Gov't, P.H.S.